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Abstract
Tumoral dissemination of ovarian cancer most commonly occurs through the intra-peritoneal route; nevertheless,
although it is rare, ovarian cancer may also metastasise through the lymphatic channels. Lymphatic diffusion of ovarian
cancer usually involves pelvic and retro-peritoneal lymph nodes. Extra-abdominal lymph nodes are rarely involved and
their detection may represent a challenge for the oncologist. We describe here two patients studied for ovarian cancer
by [18F]fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT): one
case during pre-operative staging, the other for restaging after surgery. In both cases PET examination identified extra-
abdominal lymph node tumoral spread in the left supra-clavicular space; biopsy led to a final diagnosis of recurrent
ovarian cancer. Previous reports in the literature on tumoral spread of ovarian cancer to the supra-clavicular nodes are
rare, however this possible site of metastatic involvement has to be kept in mind by oncologists and our data show that
the 18F-FDG PET/CT may be useful to disclose this unusual supra-diaphragmatic lymphatic diffusion of metastatic
lymphatic ovarian cancer.
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Introduction
Ovarian cancer has the highest mortality rate of all
gynaecologic malignancies in Europe and in the United
States[1] . This happens primarily because ovarian cancer
presents at a relatively advanced stage of the disease.
Dissemination of ovarian cancer is most common by
the intra-peritoneal route so that in the majority of
patients disease most frequently remains confined to the
peritoneal cavity[2] . Nevertheless, ovarian cancer may
also metastasize through lymphatic channels; for this
reason a lymph node metastasis classification has been
introduced into the FIGO staging.
The prognostic significance of lymph node metas-
tasis(es) in ovarian cancer is still controversial[3] and
researchers have paid most attention to investigating the
prognostic impact of para-aortic lymph node metasta-
sis[4] . Indeed, very few papers describe extra-abdominal
lymph node involvement in this type of tumour[5,6].
Positron emission tomography (PET) with [18F]fluoro-
2-deoxy-D-glucose (FDG) has emerged as an extremely
useful technique in clinical oncology. A high accuracy
of 18F-FDG PET has been proven for evaluating patients
with ovarian tumours, both for the assessment of ovarian
neoplasms before treatment and for the evaluation of
cancer recurrence[7,8].
This paper is available online at http://www.cancerimaging.org. In the event of a change in the URL address, please use the DOI
provided to locate the paper.
1470-7330/06/010020 + 04 c© 2006 International Cancer Imaging Society
Supra-clavicular metastases in ovarian cancer 21
Figure 1 18F-FDG PET/CT scan showing multiple
sites of increased FDG uptake in abdominal lymph
nodes but also in the left supra-clavicular region.
Recently hybrid PET/computed tomography (CT) has
been introduced in clinical practice, combining the
information derived from the functional imaging of18F-
FDG PET with the detailed morphological data of CT.
Preliminary reports indicate a potential usefulness of
this technique for the precise identification of cancer
spread[9] . In particular, in ovarian cancer18F-FDG
PET/CT was found to be particularly useful in identifying
abdominal recurrence[10].
We describe here two patients studied for ovarian
cancer. In both cases18F-FDG PET/CT allowed us to




Each patient, fasted for at least 6 h, was intravenously
injected with 5.3 MBq/kg of 18F-FDG; images were
recorded 60–90 min after tracer administration using a
Discovery LS-ST4 scanner (General Electric Medical
System, Waukesha, WI). The CT parameters were as
follows: 140 kV, 90 mA, 0.8 s per tube rotation, 30 mm
table speed per gantry rotation. Multi-slice technology
allowed the acquisition of four slices per tube rotation
with a thickness of 5 mm. PET studies were performed
acquiring 4 min of emission data per bed position and
35 transaxial images were reconstructed for each bed.
Scaled CT images were used for non-uniform attenuation





Figure 2 18F-FDG PET/CT scan: (a) CT image, (b)
PET image, (c) fusion PET/CT image. Focal area of
highly increased FDG uptake is shown in the left
supra-clavicular lymph nodes.
Case report 1
A 51-year-old patient was operated on June 2003
for a pelvic tumour. Pre-surgical diagnostic work-up
included abdominal-pelvic CT and ultrasound; a large
pelvic mass likely originating from the left ovary was
depicted. At laparoscopy a 10 cm mass characterised
by a combination of solid and cystic areas with
involvement of both annexials was found. The patient was
operated on by laparotomy, and total hysterectomy plus
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bilateral annexial resection and peritoneal washing were
performed. Histology indicated a poorly differentiated
cancer, infiltrating the myometrium; the peritoneal fluid
was positive for cancerous cells. The patient was
then scheduled for chemotherapy. Before an18F-FDG
PET/CT scan was obtained. PET/CT revealed multiple
sites of increased glycolytic metabolism in lymph
nodes: iliac bilaterally, left lumbar, para-caval and also
left supra-clavicular/latero-cervical (Figs 1 and 2). The
presence of supra-clavicular lymph nodes was confirmed
by ultrasound and CT, and the final diagnosis of
metastatic ovarian cancer was reached by biopsy. The
patient was then treated by chemotherapy (carboplatin
plus taxol plus topotecan) obtaining a good response (a
reduction of Ca125 from 273 to 14). The post-treatment
PET/CT was negative.
Figure 3 18F-FDG PET/CT scan revealing increased
FDG uptake in the pelvic mass and in multiple
abdominal lymph nodes (para-aortic, para-caval,
retro-crural), but also in the left supra-clavicular
lymph nodes.
Case report 2
A 65-year-old patient was admitted to our hospital in
July 2003 for complete staging and subsequently surgery
for a pelvic tumour. The patient had already undergone
hysterectomy in 1982 for fibrocystic endometriosis.
Ultrasound demonstrated the presence of a pelvic mass
with non-homogeneous echogenicity; abdominal-pelvic
CT confirmed the presence of a large mass (17× 12× 14
cm) and also showed lymph nodal involvement at para-
aortic, para-caval, retro-crural levels.18F-FDG PET/CT
was therefore performed for staging. PET/CT showed
an intense radio-tracer uptake in the pelvic mass, and
also revealed multiple hypermetabolic lymph nodes in
the para-aortic, para-caval, retro-crural and left supra-
clavicular regions (Figs 3 and 4). Biopsy confirmed a
metastatic spread of ovarian cancer. The patient was
then operated on by laparotomy, with mass excision
and bilateral annexiectomy. Histology showed a poorly
differentiated serum-papillary carcinoma. At discharge
he patient was scheduled for chemotherapy, but she
refused further treatment.
Discussion
Ovarian cancer tends physiologically to metastasise via
the lymphatic channels, mainly the intra-peritoneal route
and understanding of the sites of spread is crucial
for disease treatment[4] . Lymphatic diffusion of ovarian
cancer is commonly retained to involve mainly pelvic
lymph nodes and, subsequently, retro-peritoneal lymph
nodes[4] .
Data from the literature concerning extra-abdominal
lymph node involvement are very poor. In this respect,
it is worth noting that a recent review on this topic did
not take into account the prevalence of extra-abdominal
positive nodes[11]. The same occurred in a recent paper
reviewing nodal metastasis in ovarian cancer[12]. Con-
versely, Cormio and colleagues[5] reviewed 162 patients
with epithelial ovarian carcinoma and reported five cases
of extra-abdominal lymphatic spread. Interestingly, Zang
and colleagues[6] described their 10-years of experience
of patients with ovarian cancer presenting initially with
extra-abdominal metastases and reported a significant
number of cases with supra-clavicular and inguinal
lymph nodes metastases (6 and 5 cases, respectively).
Apart from these two papers, a case report described left
internal mammary lymph node involvement in a patient
with serious borderline ovarian tumour[13]; two cases of
intra-mammary lymph node metastases were described:
in a case of early-staged ovarian cancer[14] and in a case
of a borderline papillary ovarian tumour[15]. Lastly, we
found few cases of axillary lymph nodes calcification
in patients with metastatic ovarian carcinoma[16]. These
sporadic reports in the literature clearly indicate that
extra-abdominal lymph node spread in ovarian cancer is
possible although rare[17].
On the basis of our findings, it may be speculated
that 18F-FDG PET/CT is a useful tool and it may be
particularly useful to detect unusual extra-abdominal
nodal involvement in ovarian cancer.
Further studies on a higher number of patients are
required to elucidate the potential role of18F-FDG
PET/CT in evaluating lymphatic metastatic spread of
ovarian cancer.
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Figure 4 18F-FDG PET/CT scan: coronal images, (a) CT image, (b) PET image, (c) PET/CT fusion image. A
focal area of intense FDG uptake is shown in the left supra-clavicular lymph nodes.
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